texas oncology more breakthroughs. more victories
search
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

South Texas Clinical Trials

Texas Oncology cancer centers in South Texas participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the South Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the South Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the South Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the South Texas area and talk to you doctor to determine which clinical trial is right for you.

Bladder Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: II

Breast Cancer

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Carcinoid

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Weslaco

Phase: II

Colon Cancer

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I

Essential Thrombocythemia

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Weslaco

Phase: IV

Hematologic

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Harlingen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-McAllen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Weslaco

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Weslaco

Phase: IV

Leukemia

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: IV

Liver Cancer

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Lung Cancer

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I

Lymphomas

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Melanoma

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: I

Myelofibrosis

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: II

Neuroendocrine Tumors

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-McAllen

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Weslaco

Phase: III

Prostate Cancer

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Renal Cancer

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Sarcoma

Title: A Retrospective Observational Study of Kaposi Sarcoma in South Texas View

Indication: Sarcoma

Location: Texas Oncology-McAllen

Skin Cancer

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: II

Solid Tumors

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV

Urothelial Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II

Texas Oncology-Harlingen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Harlingen

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Harlingen

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: II

Texas Oncology-McAllen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-McAllen

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: A Retrospective Observational Study of Kaposi Sarcoma in South Texas View

Indication: Sarcoma

Location: Texas Oncology-McAllen

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-McAllen

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-McAllen

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: IV

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: I

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: II

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II

Texas Oncology-Weslaco

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Weslaco

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Weslaco

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: IV

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II

No Phase

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Harlingen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-McAllen

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Hematologic

Location: Texas Oncology-Weslaco

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-McAllen

Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Title: A Retrospective Observational Study of Kaposi Sarcoma in South Texas View

Indication: Sarcoma

Location: Texas Oncology-McAllen

Phase I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: I

Phase I/II

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Phase II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II

Phase III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-McAllen

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: III

Phase IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Weslaco

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Weslaco

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV